株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:大うつ病性障害 - 現在/将来の主要企業

PharmaPoint: Major Depressive Disorder - Current and Future Players

発行 GlobalData 商品コード 305491
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:大うつ病性障害 - 現在/将来の主要企業 PharmaPoint: Major Depressive Disorder - Current and Future Players
出版日: 2014年05月30日 ページ情報: 英文 59 Pages
概要

当レポートでは、急速に成長している世界の大うつ病性障害治療薬市場について、新規参入を含めた競合情勢に焦点をあて、競合評価、企業プロファイル、事業内容、財務状況、戦略評価と将来のシナリオなど詳細な分析をまとめ、提供いたします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場

第4章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Lundbeck
    • Forest Laboratories (Actavis)
    • Eli Lilly
    • Pfizer
    • 大塚製薬
    • AstraZeneca
    • 武田医薬品
    • Alkermes
    • Euthymics Bioscience
    • Naurex
    • e-Therapeutics

第5章 付録

図表

目次
Product Code: GDHC1035FPR

GlobalData has released its pharma report, "PharmaPoint: Major Depressive Disorder - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Major Depressive Disorder.
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Major Depressive Disorder market.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • What's the next big thing in the global Major Depressive Disorder market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Related Reports

3. Market Outlook

  • 3.1 Global
    • 3.1.1 Forecast
    • 3.1.2 Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1 Overview
  • 4.2 Trends in Corporate Strategy
  • 4.3 Company Profiles
    • 4.3.1 Lundbeck
    • 4.3.2 Forest Laboratories (Actavis)
    • 4.3.3 Eli Lilly
    • 4.3.4 Pfizer
    • 4.3.5 Otsuka Pharmaceutical
    • 4.3.6 AstraZeneca
    • 4.3.7 Takeda Pharmaceutical
    • 4.3.8 Alkermes
    • 4.3.9 Euthymics Bioscience
    • 4.3.10 Naurex
    • 4.3.11 e-Therapeutics

5. Appendix

  • 5.1 Bibliography
  • 5.2 Abbreviations
  • 5.3 Methodology
  • 5.4 Forecasting Methodology
    • 5.4.1 Diagnosed MDD Patients
    • 5.4.2 Percent of Drug-Treated Patients
    • 5.4.3 General Pricing Assumptions
    • 5.4.4 Generic Erosion
  • 5.5 Physicians and Specialists Included in this Study
  • 5.6 About the Authors
    • 5.6.1 Analyst
    • 5.6.2 Therapy Area Directors
    • 5.6.3 Global Head of Healthcare
  • 5.7 About GlobalData
  • 5.8 Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($) for MDD, 2013-2023
  • Table 2: MDD Market - Drivers and Barriers, 2013-2023
  • Table 3: Key Companies in the MDD Market in the 7MM and Australia, 2013
  • Table 4: Lundbeck's MDD Portfolio Assessment, 2013
  • Table 5: Forest (Actavis)'s MDD Portfolio Assessment, 2013
  • Table 6: Eli Lilly's MDD Portfolio Assessment, 2013
  • Table 7: Pfizer's MDD Portfolio Assessment, 2013
  • Table 8: Otsuka's MDD Portfolio Assessment, 2013
  • Table 9: AstraZeneca's MDD Portfolio Assessment, 2013
  • Table 10: Takeda's MDD Portfolio Assessment, 2013
  • Table 11: Alkermes's MDD Portfolio Assessment, 2013
  • Table 12: Euthymics Bioscience's MDD Portfolio Assessment, 2013
  • Table 13: Naurex's MDD Portfolio Assessment, 2013
  • Table 14: e-Therapeutics's MDD Portfolio Assessment, 2013
  • Table 15: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Global Sales for MDD by Region, 2013-2023
  • Figure 2: Company Portfolio Gap Analysis in MDD, 2013-2023
  • Figure 3: Lundbeck SWOT Analysis in MDD, 2013-2023
  • Figure 4: Forest (Actavis) SWOT Analysis in MDD, 2013-2023
  • Figure 5: Eli Lilly SWOT Analysis in MDD, 2013-2023
  • Figure 6: Pfizer SWOT Analysis in MDD, 2013-2023
  • Figure 7: Otsuka SWOT Analysis in MDD, 2013-2023
  • Figure 8: AstraZeneca SWOT Analysis in MDD, 2013-2023
  • Figure 9: Takeda SWOT Analysis in MDD, 2013-2023
  • Figure 10: Alkermes SWOT Analysis in MDD, 2013-2023
  • Figure 11: Euthymics Bioscience SWOT Analysis in MDD, 2013-2023
  • Figure 12: Naurex SWOT Analysis in MDD, 2013-2023
  • Figure 13: e-Therapeutics SWOT Analysis in MDD, 2013-2023
Back to Top